Talaria Global Equity Fund – Foundation

Foundation Units are now closed to new investors.

Existing Investors: Please contact Talaria on
(03) 8676 0667 to discuss your investment further.

Performance

as at 31/10/20241

1 Month3 Month6 Months1 Year3 Years (pa)5 Years (pa)7 Years (pa) 10 Years (pa) Since Inception (pa)2
Total Return %1.74 1.31 5.40 6.82 9.66 8.04 8.33 7.99 7.64
Average Market Exposure4 63% 64% 64% 61% 57% 57% 58% 59% 61%

1 Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.
2 Inception date for performance calculation is 1 October 2005.
3 Past performance is not a reliable indicator of future performance.
4 Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio.

Distribution History

FrequencyEnd PeriodCents per UnitReinvestment Price
Quarterly30-Sep-245.3809$5.2890
Quarterly30-Jun-2417.3304 $5.0482
Quarterly31-Mar-24 7.1577$5.4311
Quarterly31-Dec-239.8624$5.3614
Quarterly30-Sept-235.80605$5.4423
Quarterly30-Jun-238.1576$5.3852
Quarterly31-Mar-235.370$5.308
Quarterly30-Dec-225.45749$5.1011
Quarterly30-Sept-228.97251$4.9652
Quarterly30-Jun-2214.1354$5.0013
Quarterly31-Mar-22 5.5215 $5.0036
Quarterly31-Dec-21 5.2967 $5.0779
Quarterly30-Sep-21 6.1245$5.000
Quarterly30-Jun-21 8.876 $4.918
Download historical distributions      

Growth of $100,000 since inception6

Annual Distributions7

6 Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions. Past performance is not a reliable indicator of future performance. 7 Illustrates Distribution Returns for the Talaria Global Equity Fund – Foundation Units for the financial year ending 30 June 2024. Inception date is 1 October 2005.

Top 10 holdings8

Company NameHolding %CountrySectorDescription
Roche 5.7 Switzerland HealthcareA global leader in cancer treatments
Johnson & Johnson 5.6USAHealthcarePharmaceutical, medical devices and consumer health products company
Sanofi 5.3 France HealthcareTop 5 pharmaceutical firm with leading positions in diabetes and rare diseases
Gilead 5.2USA HealthcareLeading research based biopharmaceutical company
Bunzl 4.4United KingdomIndustrialsMultinational distribution and outsourcing business
Medtronic 3.7 USAHealthcareA leading medical devices company
Secom 3.6JapanIndustrialsJapan’s largest protective and electronic security solutions provider
Nestle 3.5SwitzerlandConsumer StaplesThe world’s largest food company measured by revenues
Henkel 3.4 Germany Consumer StaplesA multinational household products and adhesives company
Brenntag3.4 GermanyIndustrialsLargest third-party chemicals and ingredients distributor in the world

8 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector allocation10

Regional Allocation10

9,10 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.
*USA includes American Depositary Receipts (ADRs) listings.

Fund Snapshot

Management Fee Nil
LiquidityDaily
Min Investment $50,000
Availability Wholesale Clients Only
Inception Date 1 October 2005
Buy / Sell Spread 0.20% / 0.20%
DistributionsQuarterly
Download historical unit prices